低剂量新三联疗法根除血透患者幽门螺杆菌的疗效及安全性研究

目的研究以低剂量奥美拉唑为基本药物联合低剂量阿莫西林胶囊和克拉霉素片的7日新三联疗法治疗维持性血液透析患者幽门螺杆菌的疗效及安全性。方法选取22例合并幽门螺杆菌感染的血透患者为研究对象,同时选取30例各脏器功能正常的合并幽门螺杆菌患者为对照组,血透患者和对照组的服药剂量为：奥美拉唑胶囊20mg qd、阿莫西林胶囊500mg bid、克拉霉素片250mg qd,疗程均为1周,停药4周后通过组织学及碳呼气试验检测幽门螺杆菌的感染情况,比较两组的幽门螺杆菌根除率。结果血透患者幽门螺杆菌的清除率为81.8%,而非尿毒症患者为80%（P〉0.05）。所有研究对象均未发生严重的不良反应。结论低剂量新三联疗法对根除血透患者幽门螺杆菌是有效及安全的。

Helicobacter pylori eradication with a 7-day low-dose triple therapy in hemodialysis patients

OBJECTIVE To evaluate the efficacy and safety of a 7-day omeprazole-based triple therapy with low doses of amoxicillin and clarithromycin(OAC) for eradication of H.pylori infection in ESRD patients receiving hemodialysis.METHODS Twenty-two hemodialysis patients and 30 patients with normal renal function underwent upper gastrointestinal endoscopy.For eradication of H.pylori infection,a 7-day triple therapy with low-dose OAC(omeprazole 20mg daily,amoxicillin 500mg twice daily,and clarithromycin 250mg daily) regimen was used.Four weeks after the completion of the OAC regimen,the success of the H.pylori eradication therapy was determined by histological examination and rapid urease test.RESULTS Eradication was successful in 81.8% of hemodialysis patients and 80% of non-uremic patients(P>0.05).All patients completed the eradication therapy without any serious adverse effects.CONCLUSION A 7-day triple therapy with a low-dose OAC regimen was effective and safe for eradication of H.pylori infection in hemodialysis patients.